Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Björn Tackenberg

Showing results (11-20 of 82) with videos related to

Pageof 9
Sort By:
European Neurology|November 17, 2011
Economic burden in a German cohort of patients with multiple sclerosisJens Peter Reese, Axel John, Gabriele Wienemann, et al.
Plos One|February 13, 2016
Increased Frequency of T Follicular Helper Cells and Elevated Interleukin-27 Plasma Levels in Patients with PemphigusTina Hennerici, Robert Pollmann, Thomas Schmidt, et al.
Journal of Neuroimmunology|January 8, 2018
Serum titers of autoantibodies against α-synuclein and tau in child- and adulthoodIsabell Kuhn, Tobias Rogosch, Theresa I Schindler, et al.
Muscle & Nerve|April 9, 2014
Intravenous immunoglobulin maintenance treatment in myasthenia gravis: a randomized, controlled trial sample size simulationChristian Eienbröker, Florian Seitz, Anna Spengler, et al.
Muscle & Nerve|April 15, 2026
Quality of Life in Patients With Chronic Inflammatory Demyelinating PolyneuropathyTobias C Blum, Hendrik van der Wurp, David Mengel, et al.
Plos One|March 14, 2013
Myasthenia gravis: analysis of serum autoantibody reactivities to 1827 potential human autoantigens by protein macroarraysAnne Becker, Nicole Ludwig, Andreas Keller, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|December 24, 2017
Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEATjalf Ziemssen, Michael Lang, Björn Tackenberg, et al.
Seizure|January 11, 2011
Cytokines and epilepsyGang Li, Sebastian Bauer, Mareike Nowak, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 21, 2014
Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimodRobert Hoepner, Joachim Havla, Christian Eienbröker, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 27, 2013
Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patientsRebecca C Selter, Viola Biberacher, Verena Grummel, et al.
Pageof 9

Showing results (11-20 of 82) with videos related to

Sort By:
Pageof 9
European Neurology|November 17, 2011
Economic burden in a German cohort of patients with multiple sclerosisJens Peter Reese, Axel John, Gabriele Wienemann, et al.
Plos One|February 13, 2016
Increased Frequency of T Follicular Helper Cells and Elevated Interleukin-27 Plasma Levels in Patients with PemphigusTina Hennerici, Robert Pollmann, Thomas Schmidt, et al.
Journal of Neuroimmunology|January 8, 2018
Serum titers of autoantibodies against α-synuclein and tau in child- and adulthoodIsabell Kuhn, Tobias Rogosch, Theresa I Schindler, et al.
Muscle & Nerve|April 9, 2014
Intravenous immunoglobulin maintenance treatment in myasthenia gravis: a randomized, controlled trial sample size simulationChristian Eienbröker, Florian Seitz, Anna Spengler, et al.
Muscle & Nerve|April 15, 2026
Quality of Life in Patients With Chronic Inflammatory Demyelinating PolyneuropathyTobias C Blum, Hendrik van der Wurp, David Mengel, et al.
Plos One|March 14, 2013
Myasthenia gravis: analysis of serum autoantibody reactivities to 1827 potential human autoantigens by protein macroarraysAnne Becker, Nicole Ludwig, Andreas Keller, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|December 24, 2017
Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEATjalf Ziemssen, Michael Lang, Björn Tackenberg, et al.
Seizure|January 11, 2011
Cytokines and epilepsyGang Li, Sebastian Bauer, Mareike Nowak, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 21, 2014
Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimodRobert Hoepner, Joachim Havla, Christian Eienbröker, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 27, 2013
Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patientsRebecca C Selter, Viola Biberacher, Verena Grummel, et al.
Pageof 9